CHMP Recommends EU Approval for Novo Nordisk's Wegovy® 7.2 mg Single-Dose Pen for Obesity
NVO sits 27% above its 52-week low of $35.12.
Summary
European regulators have recommended approval for a more convenient single-dose pen version of Novo Nordisk's high-dose Wegovy® (7.2 mg) for obesity, paving the way for an EU launch in Q3 2026.
Key Events · Product Development and Regulatory · NVO
-
Positive CHMP Opinion
The Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Wegovy® 7.2 mg in a single-dose pen for people living with obesity in the EU.
-
Enhanced Convenience
This new formulation offers a more convenient, once-weekly single-dose injection, improving patient experience compared to the current multi-injection regimen for the 7.2 mg dose in the EU.
-
Expected EU Launch
Novo Nordisk anticipates launching the Wegovy® 7.2 mg single-dose pen in the EU in Q3 2026.
-
Proven Efficacy
The 7.2 mg dose demonstrated an average weight loss of 20.7% in the STEP UP trial, with approximately one-third of patients achieving 25% or greater weight loss.
Analysis · NVO · Life Sciences
The positive opinion from the European Medicines Agency's CHMP for the single-dose pen formulation of Wegovy® 7.2 mg is a significant regulatory milestone. This approval enhances patient convenience and adherence for a key growth product in the EU market, potentially boosting sales and market penetration for Novo Nordisk's leading obesity treatment.
At the time of this filing, NVO was trading at $44.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $195.9B. The 52-week trading range was $35.12 to $81.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.